Indaptus Therapeutics (INDP) CEO details 8.44% common stock stake

Rhea-AI Filing Summary

Indaptus Therapeutics CEO Junyi Dai reports his current ownership stake in the company’s common stock. He beneficially owns 11,250,000 shares, representing 8.44% of Indaptus Therapeutics’ common stock, based on 133,242,324 shares outstanding as of June 24, 2026.

Dai acquired these shares through a Securities Purchase Agreement dated March 19, 2026, using personal funds of $1,156,642.43 to buy Series AA and Series AAA Preferred Stock that later converted into common shares. The filing notes that his percentage ownership fell by more than 1% solely because the company issued additional shares in a private placement on June 17, 2026; he did not buy or sell any common shares in connection with that event.

Key Figures

Beneficial ownership: 11,250,000 shares Ownership percentage: 8.44% Shares outstanding: 133,242,324 shares +3 more

6 metrics

Beneficial ownership 11,250,000 shares Common stock beneficially owned by Junyi Dai

Ownership percentage 8.44% Percent of common stock class represented by 11,250,000 shares

Shares outstanding 133,242,324 shares Common stock outstanding as of June 24, 2026

Purchase amount $1,156,642.43 Personal funds used by Junyi Dai to purchase Series AAA Preferred Stock

Sole voting power 11,250,000 shares Shares over which Dai has sole voting power

Sole dispositive power 11,250,000 shares Shares over which Dai has sole dispositive power

Key Terms

beneficially owns, Securities Purchase Agreement, Series AAA Preferred Stock, private placement, +1 more

5 terms

beneficially owns financial

"Junyi Dai beneficially owns 11,250,000 shares of the Issuer's Common Stock."

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

Securities Purchase Agreement financial

"Such shares were acquired pursuant to the Securities Purchase Agreement, dated as of March 19, 2026"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

Series AAA Preferred Stock financial

"The Series AAA Preferred Stock was purchased by Mr. Dai pursuant to the Securities Purchase Agreement"

private placement financial

"upon the closing of the Issuer's private placement on June 17, 2026."

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

Schedule 13D financial

"previously filed a statement on Schedule 13G to report the acquisition that is the subject of this"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 06/26/2026 - 08:01 PM Accepted by SEC EDGAR 06/26/2026 - 08:00 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

Indaptus Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

45339J105

(CUSIP Number)

Junyi Dai
c/o Indaptus Therapeutics, Inc.,, 3 Columbus Circle, 15th Floor,
New York, NY, 10019
(646) 427-2727

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/24/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 45339J105

1

Name of reporting person

Dai Junyi

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

AUSTRALIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 11,250,000.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 11,250,000.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

11,250,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.44 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Junyi Dai beneficially owns 11,250,000 shares of the Issuer's Common Stock. Such shares were acquired pursuant to the Securities Purchase Agreement, dated as of March 19, 2026 (the "Purchase Agreement"), and were issued upon the conversion of the Issuer's Series AA and Series AAA Preferred Stock in connection with the closing of the transaction on March 23, 2026. All percentage calculations herein are based on 133,242,324 shares of Common Stock outstanding of the issuer as of June 24, 2026, based on information provided in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 24, 2026. Please also refer to the Schedule 13D filed by Yun Yao on behalf of Yun Yao, Sino Lion Ventures Limited, Chenhao Xu, Junyi Dai, Ting Yang and Lina Deng with the Securities and Exchange Commission on March 30, 2026 and all amendments to date.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.01 per share
(b)	Name of Issuer: Indaptus Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: c/o Indaptus Therapeutics, Inc., 3 Columbus Circle, 15th Floor, New York, NEW YORK , 10019.
Item 1 Comment: Explanatory Note. This Amendment No. 2 ("Amendment No. 2") to Schedule 13D relates to the common stock, par value $0.01 per share (the "Common Stock") of Indaptus Therapeutics Inc., a Delaware corporation (the "Issuer"), and amends and supplements the initial statement on Schedule 13D originally filed by Yun Yao on behalf of Yun Yao, Sino Lion Ventures Limited, Chenhao Xu, Junyi Dai ("Reporting Person"), Ting Yang, and Lina Deng with the Securities and Exchange Commission ("SEC") on March 30, 2026, as amended by Amendment No. 1 filed on April 29, 2026 to report the disbandment of such group (collectively, the "Initial Schedule 13D", and as amended and supplemented by this Amendment No. 2, the "Schedule 13D"). Capitalized terms used but not defined in this Amendment No. 2 shall have the same meanings ascribed to them in the Initial Schedule 13D.
Item 2.	Identity and Background
(a)	Mr. Junyi Dai, an individual.
(b)	Mr. Dai's address is c/o Indaptus Therapeutics, Inc., 3 Columbus Circle, 15th Floor, New York, NY, 10019.
(c)	Mr. Dai's present principal occupation is the chief executive officer and chairman of Indaptus Therapeutics, Inc.
(d)	During the last five years, Mr. Dai has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, Mr. Dai has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, which as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, United States federal or state securities laws or finding any violation with respect to such laws.
(f)	Mr. Dai is a citizen of the Australia.
Item 3.	Source and Amount of Funds or Other Consideration
	The Series AAA Preferred Stock was purchased by Mr. Dai pursuant to the Securities Purchase Agreement, dated as of March 19, 2026 (the "Purchase Agreement") between David Lazar, Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng. The Purchase Agreement closed on March 23, 2026. Mr. Dai used personal funds in the aggregate amount of $1,156,642.43 to fund his purchase.
Item 4.	Purpose of Transaction
	The information set forth in Item 4 in the Initial Schedule 13D is incorporated herein by reference. This Amendment No. 2 is being filed to report a decrease of more than 1% in the percentage of the outstanding Common Stock beneficially owned by the Reporting Person, resulting solely from the increase in the number of shares of Common Stock issued and outstanding upon the closing of the Issuer's private placement on June 17, 2026. The Reporting Person did not acquire or dispose of any shares of Common Stock in connection therewith.
Item 5.	Interest in Securities of the Issuer
(a)	The information contained on the cover pages to this Schedule 13D is incorporated herein by reference. As of the date hereof, there are 133,242,324 shares of Common Stock outstanding as of June 24, 2026, as calculated based on the Issuer's Form 8-K filed with the SEC on June 24, 2026.
(b)	The following table sets forth the number of Common Stock as to which the Reporting Person has (i) the sole power to vote or direct the vote, (ii) shared power to vote or to direct the vote, (iii) sole power to dispose or to direct the disposition, or (iv) shared power to dispose or to direct disposition:
(c)	The Reporting Person have not effected any transaction in the shares of Common Stock during the past 60 days.
(d)	No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the common stock beneficially owned by the Reporting Person.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The information set forth in Item 6 in the Initial Schedule 13D is incorporated herein by reference. The information set forth in Item 3 and Item 4 above is incorporated herein by reference.
Item 7.	Material to be Filed as Exhibits.
	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dai Junyi

Signature:	/s/ Junyi Dai
Name/Title:	Junyi Dai
Date:	06/26/2026

FAQ

What ownership stake does Junyi Dai report in Indaptus Therapeutics (INDP)?

Junyi Dai reports beneficial ownership of 11,250,000 Indaptus Therapeutics common shares, representing 8.44% of the company’s outstanding stock as of June 24, 2026, based on 133,242,324 shares outstanding.

Did Junyi Dai buy or sell Indaptus (INDP) shares in this Schedule 13D/A?

The filing states that Junyi Dai did not acquire or dispose of any Indaptus common shares in connection with this update. His reported percentage changed only because the company issued additional shares in a June 17, 2026 private placement.

How did Junyi Dai acquire his Indaptus Therapeutics (INDP) position?

He acquired his stake through a Securities Purchase Agreement dated March 19, 2026, purchasing Series AA and Series AAA Preferred Stock with $1,156,642.43 of personal funds. These preferred shares later converted into 11,250,000 common shares at closing on March 23, 2026.

Why did Junyi Dai’s ownership percentage in Indaptus (INDP) decrease?

His ownership percentage decreased by more than 1% because Indaptus issued additional common shares in a private placement that closed on June 17, 2026. The filing explains that this dilution, not any trades by Dai, reduced his percentage.

What voting and dispositive power does Junyi Dai hold over Indaptus (INDP) shares?

The filing reports that Junyi Dai has sole voting power and sole dispositive power over 11,250,000 Indaptus common shares. It also notes he has no shared voting power and no shared dispositive power over any Indaptus shares.

What is the outstanding share count for Indaptus Therapeutics (INDP) cited in this filing?

The document states that 133,242,324 shares of Indaptus Therapeutics common stock were outstanding as of June 24, 2026. This figure, taken from the company’s Form 8-K filed that day, is used to calculate Junyi Dai’s 8.44% ownership.